Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 4, pp 662–668 | Cite as

Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients

  • Jing-jing Huang
  • Bing Chen
  • Jiong Hu
  • Wan-Hua YangEmail author
Short Research Report

Abstract

Background Optimization of the area under the concentration–time curve (AUC) of busulfan, an essential component of conditioning regimens, improves the outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT). Traditional sampling methods for calculating AUC require multiple sampling. Objective To establish a limited sampling strategy for predicting the AUC0-12 of intravenous busulfan for Chinese adult patients prior to HSCT. Methods The pharmacokinetics of twice-daily intravenous busulfan was studied in forty-five Chinese adult patients. Limited sampling models were established by the multiple linear regression analysis. The prediction error (PE) and the absolute prediction error (APE) were calculated to evaluate predictive accuracy. The agreement between the predicted and actual AUC0-12 was investigated by the Bland–Altman analysis. The accuracy and robustness of the models was validated by the bootstrap analysis. Results The AUC0-12 values of the 1st and 7th doses of busulfan were 1491 ± 403.7 and 1908 ± 518.5 μmol L−1 min, respectively. The 2-sample model suggested that the predicted AUC0-12 of twice-daily intravenous busulfan could be calculated using the following equation: AUC0-12 = 40.017 + 0.955 × C3 + 1.088 × C6 with r2 = 0.919. The mean PE and APE of the model were 0.52 ± 7.67 and 6.32 ± 4.27%, respectively. Conclusion The 2-sample model is an effective and reliable approach to predict the AUC0-12 of twice-daily intravenous busulfan in Chinese adult patients.

Keywords

Busulfan Hematopoietic stem cell transplantation Pharmacokinetics Sampling strategy 

Notes

Acknowledgements

We are thankful to all nurses in department of Blood and Marrow Transplantation for their assistance.

Funding

This work is funded by the National Natural Science Foundation (81503137).

Conflicts of interest

The authors declare that they have no conflicts of interest to disclose.

References

  1. 1.
    Mccune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Drug Metab Toxicol. 2009;5(8):957–69.CrossRefGoogle Scholar
  2. 2.
    Yin J, Xiao Y, Zheng H, Zhang YC. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. Bone Marrow Transplant. 2015;50(5):696–705.CrossRefPubMedGoogle Scholar
  3. 3.
    Kellogg MD, Law T, Sakamoto M, Rifai N. Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit. 2005;27(5):625–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS, et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stern cell transplantation. Biol Blood Marrow Transplant. 2002;8(9):486–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE, Vaughan WP, et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002;8(11):619–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) forhematologic malignancies prior to allogeneic stem cell transplantation:a phase II study. Biol Blood Marrow Transplant. 2002;8(3):145–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Buffery PJ, Allen KM, Chin PK, Moore GA, Barclay ML, Begg EJ, et al. Thirteen years’ experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Ther Drug Monit. 2014;36(1):86–92.PubMedGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Jing-jing Huang
    • 1
  • Bing Chen
    • 1
  • Jiong Hu
    • 2
  • Wan-Hua Yang
    • 1
    Email author
  1. 1.Department of PharmacyRuijin Hospital, Shanghai JiaoTong University School of MedicineShanghaiChina
  2. 2.Department of Blood and Marrow TransplantationRuijin Hospital, Shanghai JiaoTong University School of MedicineShanghaiChina

Personalised recommendations